# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

# FORM 8-K

### **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 08, 2024

# **TerrAscend Corp.**

(Exact name of Registrant as Specified in Its Charter)

Canada (State or Other Jurisdiction of Incorporation)

77 City Centre Drive Suite 501 Mississauga, Ontario, Canada

(Address of Principal Executive Offices)

000-56363 (Commission File Number) Not applicable (IRS Employer Identification No.)

> L5B 1M5 (Zip Code)

Registrant's Telephone Number, Including Area Code: 844 628-3100

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

D Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

	Trading	
Title of each class	Symbol(s)*	Name of each exchange on which registered
N/A	TSNDF	N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company 🗵

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

\* The registrant's common shares, no par value, trade over-the-counter on OTCQX Best Market under the trading symbol "TSNDF".

### Item 2.02 Results of Operations and Financial Condition.

On August 8, 2024, TerrAscend Corp. (the "Company") issued a press release announcing its financial results and business highlights for the quarter ended June 30, 2024. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference.

The information in this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

#### Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Press Release, dated August 8, 2024.

104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

## TerrAscend Corp.

Date: August 8, 2024

By: /s/ Keith Stauffer Keith Stauffer

Keith Stauffer Chief Financial Officer



## **TerrAscend Reports Second Quarter 2024 Financial Results**

Net Revenue of \$77.5 million, an increase of 7.5% year-over-year

Cash Flow from continuing operations of \$13.1 million and Free Cash Flow<sup>1</sup> of \$11.7 million

#1 market share position in New Jersey throughout first half of 2024

**TORONTO, August 8, 2024** - TerrAscend Corp. ("TerrAscend" or the "Company") (TSX: TSND, OTCQX: TSNDF), a leading North American cannabis company, today reported its financial results for the second quarter ended June 30, 2024. All amounts are expressed in U.S. dollars and are prepared under U.S. Generally Accepted Accounting Principles ("GAAP"), unless indicated otherwise. The financial results of the Company include all entities that are consolidated in the Company's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024 (the "Consolidated Entities"). Any references in this press release to TerrAscend or the Company include references to the Company and the Consolidated Entities.

The following financial measures are reported as results from continuing operations due to the shutdown of the Company's licensed producer business in Canada, which is reported as discontinued operations through September 30, 2023. All historical periods have been restated accordingly.

#### Second Quarter 2024 Financial Highlights

- •Net Revenue was \$77.5 million, compared to \$72.1 million, an increase of 7.5% year-over-year.
- •Gross Profit Margin was 48.6%, compared to 50.2% in Q2 2023.
- •GAAP Net loss from continuing operations was \$6.2 million, compared to a net loss of \$12.9 million in Q2 2023.
- •EBITDA from continuing operations<sup>1</sup> was \$18.6 million, compared to \$6.5 million in Q2 2023, an increase of 186% year-over-year.
- Adjusted EBITDA from continuing operations<sup>1</sup> was \$15.6 million, compared to \$12.8 million in Q2 2023, an increase of 21.9% year-over-year.
- •Adjusted EBITDA Margin from continuing operations<sup>1</sup> was 20.2%, compared to 17.8% in Q2 2023.
- •Net Cash provided by continuing operations was \$13.1 million compared to \$1.8 million in Q2 2023.
- Free Cash Flow<sup>1</sup> was \$11.7 million compared to negative \$0.2 million in Q2 2023.

"For the second quarter, revenue and EBITDA increased materially year-over-year and we delivered another quarter of positive free cash flow," stated Jason Wild, Executive Chairman of TerrAscend. "We have the right team, high-performing assets, and a major differentiation in having a 'wide open map'. This will enable us to strike accretive deals to enter attractive new states via best in breed operators. We are closing in on multiple transactions to expand our geographic footprint and the recent closing of our \$140 million term loan provides financial flexibility and fuel to execute this growth strategy. We can't wait to share more details, when appropriate."

#### Financial Summary Q2 2024 and Comparative Periods

All figures are restated for the Canadian business recorded as discontinued operations through Q3 2023.

(in millions of U.S. Dollars)	Q2 2024	Q2 2023
Revenue, net	77.5	72.1
Year-over-Year increase	7.5 %	12.7 %
Gross profit	37.7	36.2
Gross profit margin	48.6 %	50.2 %
General & Administrative expenses	24.1	30.5
Share-based compensation expense (included in G&A expenses above)	2.0	2.0
G&A as a % of revenue, net	31.1 %	42.3 %
Net loss from continuing operations	(6.2)	(12.9)
EBITDA from continuing operations <sup>1</sup>	18.6	6.5
Adjusted EBITDA from continuing operations <sup>1</sup>	15.6	12.8
Adjusted EBITDA Margin from continuing operations <sup>1</sup>	20.2 %	17.8 %
Net cash provided by operations - continuing operations	13.1	1.8
Free Cash Flow <sup>1</sup>	11.7	(0.2)

1. EBITDA from continuing operations, Adjusted EBITDA from continuing operations, Adjusted EBITDA Margin from continuing operations, and Free Cash Flow are non-GAAP measures defined in the section titled "Definition and Reconciliation of Non-GAAP Measures" below and reconciled to the most directly comparable GAAP measure, at the end of this release.

#### Second Quarter 2024 Business and Operational Highlights

- •Achieved 8th consecutive quarter of positive cash flow provided by continuing operations.
- •Achieved #1 market share position in New Jersey throughout the first half of 2024, according to BDSA.
- •Doubled Pennsylvania wholesale revenue year-over-year.
- •Doubled New Jersey wholesale revenue year-over-year.
- •Grew Maryland wholesale revenue by 117% year-over-year.
- •Delivered 40% gross margin in Michigan for the third consecutive quarter.
- •Celebrated the opening of new Detroit dispensary, GAGE 313.
- ·Relocated and opened dispensary in Nottingham, Maryland.
- •Expanded cultivation capacity at Hagerstown, Maryland facility.

#### Subsequent Events

•Closed on a senior secured term loan for gross proceeds of \$140 million carrying an interest rate of 12.75%, maturing in August 2028, and containing no prepayment penalties or warrants.

#### Second Quarter 2024 Financial Results

Net revenue for the second quarter of 2024 was \$77.5 million, an increase of 7.5% compared to \$72.1 million for the second quarter of 2023. This growth was driven by a 75% increase in wholesale revenue led by New Jersey, Pennsylvania and Maryland, partially offset by an 8.7% decline year-over-year in retail revenue mainly driven by New Jersey and Michigan.

Gross profit margin for the second quarter of 2024 was 48.6% as compared to 50.2% in the second quarter of 2023. The year-over-year decrease of 160 basis points was driven by channel mix shift and retail price compression in New Jersey, partially offset by margin expansion in both Michigan and Maryland.

General & Administrative expenses (G&A) for the second quarter of 2024 were \$24.1 million as compared to \$30.5 million in the second quarter of 2023. G&A as a percent of revenue was 31.1% in the second quarter of 2024, compared to 42.3% in the second quarter of 2023. The reduction in G&A as a percent of revenue was driven by a \$4.2 million reversal of a bad debt provision related to a legal settlement, combined with other underlying reductions across the business, while growing revenue by 7.5% year-over-year.

Net loss from continuing operations for the second quarter of 2024 was \$6.2 million, compared to a net loss of \$12.9 million in the second quarter of 2023. The improvement was driven by revenue growth while maintaining relatively stable gross profit margins and materially reducing G&A expenses.

Adjusted EBITDA from continuing operations for the second quarter of 2024 grew 21.9% year-over-year to \$15.6 million, representing a 20.2% Adjusted EBITDA margin, as compared to \$12.8 million and 17.8% in the second quarter of 2023. The year-over-year improvement of 240 basis points was driven by G&A expense leverage, partially offset by the decline in gross margin.

#### **Balance Sheet and Cash Flow**

Cash and cash equivalents, including restricted cash, were \$30.5 million as of June 30, 2024, compared to \$25.7 million as of March 31, 2024. Net cash provided by continuing operations was \$13.1 million for the second quarter of 2024 compared to \$1.8 million in the second quarter of 2023. This represented the Company's eighth consecutive quarter of positive cash flow from continuing operations. The second quarter of 2024 included an \$8.4 million federal tax refund related to certain amended tax returns for Consolidated Entities. Capex spending was \$1.4 million in the second quarter of 2024 mainly related to the completion of the Company's Hagerstown, Maryland expansion which doubled the output capacity at that site. Free cash flow was \$11.7 million as compared to (\$0.2) million in the second quarter of 2023. During the second quarter of 2024, payments were made related to \$5.8 million of debt paydown and \$1.2 million for distributions to the Company's New Jersey minority partners.

Subsequent to the end of the quarter, the Company closed on a senior secured term loan (the "Loan") for gross proceeds of \$140 million from funds managed by FocusGrowth Asset Management, LP ("FocusGrowth"), a leading capital provider to the cannabis sector, along with other members of a loan syndicate. The Loan includes an initial draw of \$114 million in gross proceeds by certain of the Consolidated Entities in Pennsylvania, Maryland and California, with a second draw of \$26 million in gross proceeds expected in September 2024 by the Consolidated Entities in Michigan. The Loan carries an interest rate of 12.75%, matures in August 2028, contains no prepayment penalties, and is guaranteed by the Company and TerrAscend USA, Inc. No warrants were issued as part of the Loan. The proceeds from the initial draw were used to retire the Company's existing indebtedness in Pennsylvania with the remainder available for potential M&A transactions focused on geographic expansion. The proceeds from the second draw will be used to retire the Company's existing indebtedness in Michigan.

As of August 7, 2024, there were approximately 368 million basic shares of the Company issued and outstanding, including 291 million Company common shares, 13 million Company preferred shares, as converted, and 63 million Company exchangeable shares. Additionally, there are 44 million warrants and options outstanding at a weighted average price of \$3.84.

#### **Conference Call**

TerrAscend will host a conference call today, August 8, 2024, to discuss these results. Jason Wild, Executive Chairman, Ziad Ghanem, President and Chief Executive Officer, and Keith Stauffer, Chief Financial Officer, will host the call starting at 5:00 p.m. Eastern time. A question-and-answer session will follow management's presentation.

Date:	Thursday, August 8, 2024
Time:	5:00 p.m. Eastern Time
Webcast:	https://app.webinar.net/LVQnp1BkreY
Dial-in Number:	1-888-664-6392
Replay:	416-764-8677 or 1-888-390-0541
	Available until 12:00 midnight Eastern Time Thursday, August 22, 2024 Replay Entry Code: 532477#

Financial results and analyses are available on the Company's website (www.terrascend.com), the SEC's Electronic Data Gathering and Analysis Retrieval System (EDGAR) (www.sec.gov), and SEDAR+ (www.sedarplus.ca).

# The Toronto Stock Exchange ("TSX") has neither approved nor disapproved the contents of this news release. Neither the TSX nor any securities regulator accepts responsibility for the adequacy or accuracy of this release.

#### About TerrAscend

TerrAscend is a leading TSX-listed cannabis company with interests across the North American cannabis sector, including vertically integrated operations in Pennsylvania, New Jersey, Maryland, Michigan and California through TerrAscend Growth Corp. and retail operations in Canada through TerrAscend Canada Inc.. TerrAscend operates The Apothecarium, Gage and other dispensary retail locations as well as scaled cultivation, processing, and manufacturing facilities in its core markets. TerrAscend's cultivation and manufacturing practices yield consistent, high-quality cannabis, providing industry-leading product selection to both the medical and legal adult-use markets. The Company owns or licenses several synergistic businesses and brands including Gage Cannabis, The Apothecarium, Cookies, Lemonnade, Ilera Healthcare, Kind Tree, Legend, State Flower, Wana, and Valhalla Confections. For more information visit www.terrascend.com.

#### **Caution Regarding Cannabis Operations in the United States**

Investors should note that there are significant legal restrictions and regulations that govern the cannabis industry in the United States. Cannabis remains a Schedule I drug under the US Controlled Substances Act, making it illegal under federal law in the United States to, among other things, cultivate, distribute, or possess cannabis in the United States. Financial transactions involving proceeds generated by, or intended to promote, cannabis-related business activities in the United States may form the basis for prosecution under applicable US federal money laundering legislation.

While the approach to enforcement of such laws by the federal government in the United States has trended toward non-enforcement against individuals and businesses that comply with medical or adult-use cannabis programs in states where such programs are legal, strict compliance with state laws with respect to cannabis will neither absolve TerrAscend of liability under U.S. federal law, nor will it provide a defense to any federal proceeding which may be brought against TerrAscend. The enforcement of federal laws in the United States is a significant risk to the business of TerrAscend and any proceedings brought against TerrAscend thereunder may adversely affect TerrAscend's operations and financial performance.

#### **Forward Looking Information**

This news release contains "forward-looking information" within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, "may", "would", "could", "will", "likely", "expect", "anticipate", "believe, "intend", "plan", "forecast", "project", "estimate", "outlook" and other similar expressions, and include statements with respect to the Company's expectations regarding the financial and other benefits of the Loan to the Company's operations and growth strategy; the Company's expected use of proceeds from the Loan; the Company's potential expansion into other markets and U.S federal regulatory reform. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management's expected and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment, and the availability of licenses, approvals and permits.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to, current and future market conditions; risks related to federal, state, provincial, territorial, local and foreign government laws, rules and regulations, including federal and state laws in the United States relating to cannabis operations in the United States; and the risk factors set out in the Company's most recently filed MD&A, filed with the Canadian securities regulators and available under the Company's profile on SEDAR+ at www.sedarplus.ca and in the section titled "Risk Factors" in the Company's Annual Report for the year ended December 31, 2023 filed with the Securities and Exchange Commission on March 14, 2024.

The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether, as a result of new information, future events, or results or otherwise, other than as required by applicable securities laws.

#### **Definition and Reconciliation of Non-GAAP Measures**

In addition to reporting the financial results in accordance with GAAP, the Company reports certain financial results that differ from what is reported under GAAP. Non-GAAP measures used by management do not have any standardized meaning prescribed by GAAP and may not be comparable to similar measures presented by other companies. The Company believes that certain investors and analysts use these measures to measure a company's ability to meet other payment obligations or as a common measurement to value companies in the cannabis industry, and the Company calculates: (i) EBITDA from continuing operations and Adjusted EBITDA from continuing operations as net loss, adjusted to exclude provision for income taxes, finance expenses, depreciation and amortization, share-based compensation, loss from revaluation of contingent consideration, gain on fair value of derivative liabilities and purchase option derivative assets, gain on lease termination, and certain other items, which management believes is not reflective of the ongoing operations and performance, (ii) Adjusted EBITDA Margin from continuing operations as EBITDA from continuing operations adjusted for certain material non-cash items such as share-based compensation, loss from revaluation of contingent consideration, gain on fair value of derivative liabilities and purchase option derivative espenses is not reflective of the ongoing operations and performance, (ii) Adjusted EBITDA Margin from contingent consideration, gain on fair value of derivative liabilities and purchase option derivative assets, gain on lease termination, certain other items, which management believes is not reflective of the ongoing operations and performance of the Company, (iii) Free Cash Flow as net cash provided by operating activities from continuing operations as presented in the Consolidated Statements of Cash Flows, less capital expenditures for provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in ac

For more information regarding TerrAscend: Keith Stauffer Chief Financial Officer ir@terrascend.com 855-837-7295

# TerrAscend Corp.

**Consolidated Balance Sheet** (Amounts expressed in thousands of United States dollars, except for share and per share amounts)

	т	At ine 30, 2024	At December	
Assets	JU	ine 30, 2024	December	31, 2023
Current assets				
Cash and cash equivalents	\$	27,378	\$	22,241
Restricted cash		3,113		3,106
Accounts receivable, net		16,799		19,048
Investments		1,737		1,913
Inventory		51,009		51,683
Prepaid expenses and other current assets		4,771		4,898
Total current assets		104,807		102,889
Non-current assets				
Property and equipment, net		193,340		196,215
Deposits		284		337
Operating lease right of use assets		41,645		43,440
Intangible assets, net		212,515		215,854
Goodwill		106,929		106,929
Other non-current assets		724		854
Total non-current assets		555,437		563,629
Total assets	\$	660,244	\$	666,518
Liabilities and shareholders' equity				
Current liabilities	¢.	46.010	¢.	40.007
Accounts payable and accrued liabilities	\$	46,918	\$	49,897
Deferred revenue		4,699		4,154
Loans payable, current		15,946		137,737
Contingent consideration payable, current		2,632		6,446
Operating lease liability, current		2,330		1,244
Derivative liability, current		899 93		2 020
Lease obligations under finance leases, current		3,184		2,030 4,775
Corporate income tax payable Other current liabilities		756		4,773
Total current liabilities		77,457		207,000
Non-current liabilities		//,+5/		207,000
Loans payable, non-current		171,926		61,633
Operating lease liability, non-current		42,654		45,384
Lease obligations under finance leases, non-current		2,140		407
Derivative liability, non-current		2,253		5,162
Convertible debt		8,126		7,266
Deferred income tax liability		16,760		17,175
Contingent consideration payable, non-current		2,109		
Liability on uncertain tax position and other long term liabilities		110,673		81,751
Total non-current liabilities		356,641		218,778
Total liabilities		434,098		425,778
Commitments and contingencies				
Shareholders' equity				
Share capital				
Series A, convertible preferred stock, no par value, unlimited shares authorized; 12,350 and 12,350 shares outstanding as of June 30, 2024 and December 31, 2023, respectively		_		_
Series B, convertible preferred stock, no par value, unlimited shares authorized; 600 and 600 shares outstanding as of June 30, 2024 and December 31, 2023, respectively		_		
Series C, convertible preferred stock, no par value, unlimited shares authorized; nil and nil shares outstanding as of June 30, 2024 and December 31, 2023, respectively		_		_
Series D, convertible preferred stock, no par value, unlimited shares authorized; nil and nil shares outstanding as of June 30, 2024 and December 31, 2023, respectively		—		_
Proportionate voting shares, no par value, unlimited shares authorized; nil and nil shares outstanding as of June 30, 2024 and December 31, 2023, respectively				
Exchangeable shares, no par value, unlimited shares authorized; 63,492,038 and 63,492,038 shares outstanding as of June 30, 2024 and December 31, 2023, respectively		—		—
Common shares, no par value, unlimited shares authorized; 291,507,430 and 288,327,497 shares outstanding as of June 30, 2024 and December 31, 2023, respectively				_
Additional paid in capital		945,797		944,859
Accumulated other comprehensive income		2,457		1,799
Accumulated deficit		(723,590)		(704,162)
Non-controlling interest		1,482		(1,756)
Total shareholders' equity		226,146		240,740
Total liabilities and shareholders' equity	\$	660,244	\$	666,518

# TerrAscend Corp.

**Consolidated Statements of Operations and Comprehensive Loss** (Amounts expressed in thousands of United States dollars, except for share and per share amounts)

	J	For the Three Months Ended June 30, 2024 June 30, 2		hs Ended une 30, 2023			the Six Months Ended ), 2024 June 30, 2023		
Revenue, net	\$	77,523	\$	72,124	\$	158,156	\$	141,522	
Cost of sales		39,840		35,898		81,742		71,396	
Gross profit		37,683		36,226		76,414		70,126	
Gross prom		57,005		50,220		/0,414		/0,120	
Operating expenses:									
General and administrative		24,060		30,476		52,068		58,206	
Amortization and depreciation		2,190		2,242		4,405		4,271	
Impairment of property and equipment and right of use assets		_		_		2,438		28	
Other operating (income) expense		(1,186)		10		(1,186)		317	
Total operating expenses		25,064		32,728		57,725		62,822	
Income from operations		12,619		3,498		18,689		7,304	
Other expense (income)									
Loss from revaluation of contingent consideration		1,827		—		3,220		_	
Gain on fair value of derivative liabilities and purchase option derivative assets		(2,922)		(215)		(1,939)		(653	
Finance and other expenses		8,891		8,171		17,480		18,258	
Transaction and restructuring costs				389				392	
Unrealized and realized foreign exchange loss (gain)		104		(101)		389		(132	
Unrealized and realized loss on investments		227		1,661		227		2,360	
Income (loss) from continuing operations before provision for income taxes		4,492		(6,407)		(688)		(12,921	
Provision for income taxes		10,729		6,448		20,400		19,112	
Net loss from continuing operations	\$	(6,237)	\$	(12,855)	\$	(21,088)	\$	(32,033	
Discontinued operations:									
Loss from discontinued operations, net of tax	\$	_	\$	(621)	\$	_	\$	(4,212	
Net loss	<u>\$</u>	(6,237)	\$	(13,476)	\$	(21,088)	\$	(36,245	
Foreign currency translation adjustment		(260)		408		(658)		755	
Comprehensive loss	\$	(5,977)	\$	(13,884)	\$	(20,430)	\$	(37,000	
		ŕ				, in the second s			
Net loss from continuing operations attributable to:				(14.000		(25.225		(26.262	
Common and proportionate Shareholders of the Company	\$	(8,180)	\$	(14,998)	\$	(25,235)	\$	(36,362	
Non-controlling interests	\$	1,943	\$	2,143	\$	4,147	\$	4,329	
Comprehensive loss attributable to:									
Common and proportionate Shareholders of the Company	\$	(7,920)	\$	(16,027)	\$	(24,577)	\$	(41,329	
Non-controlling interests	\$	1,943	\$	2,143	\$	4,147	\$	4,329	
Net loss per share - basic:									
Continuing operations	\$	(0.03)	\$	(0.05)	\$	(0.09)	\$	(0.13	
Discontinued operations		_		_		_		(0.02	
Net loss per share - basic	\$	(0.03)	\$	(0.05)	\$	(0.09)	\$	(0.15	
Weighted average number of outstanding common shares		291,488,661		275,186,279		291,053,614		271,223,233	
Net loss per share - diluted:									
Continuing operations	\$	(0.03)	\$	(0.05)	\$	(0.09)	\$	(0.13	
Discontinued operations		_				—	\$	(0.02	
Net loss per share - diluted	\$	(0.03)	\$	(0.05)	\$	(0.09)	\$	(0.15	
Weighted average number of outstanding common shares, assuming dilution		291,488,661		275,186,279		291,053,614		271,223,233	

# TerrAscend Corp.

Consolidated Statements of Cash Flows (Amounts expressed in thousands of United States dollars, except for share and per share amounts)

	For the Six Months E June 30, 2024	nded June 30, 2023
Operating activities	June 30, 2024	June 30, 2025
Net loss from continuing operations	\$ (21,088) \$	(32,033
Adjustments to reconcile net loss to net cash provided by operating activities		
Non-cash adjustments of inventory	_	1,081
Accretion expense	8,375	5,673
Depreciation of property and equipment and amortization of intangible assets	9,993	9,761
Amortization of operating right-of-use assets	1,481	932
Share-based compensation	3,446	3,694
Deferred income tax (recovery) expense	(415)	815
Gain on fair value of derivative liabilities and purchase option derivative assets	(1,939)	(653
Gain on disposal of fixed assets	(17)	345
Unrealized and realized loss on investments	227	2,410
Loss from revaluation of contingent consideration	3,220	—
Impairment of property and equipment and right of use assets	2,438	_
Gain on lease termination	(1,169)	—
Bad debt recovery	(1,307)	(23
Unrealized and realized foreign exchange loss (gain)	389	(132)
Changes in operating assets and liabilities	1.000	
Receivables	1,358	318
Inventory	1,970	(7,851
Prepaid expense and other current assets	119	(319)
Deposits	53	431
Other assets	77	714
Accounts payable and accrued liabilities and other payables	(8,019)	4,089
Operating lease liability	(1,147)	(337
Other liability	(536)	(173)
Uncertain tax position liabilities	29,917	1,258
Corporate income tax payable	(1,591)	22,127
Deferred revenue	545	157
Net cash provided by operating activities- continuing operations	26,380	12,284
Net cash used in operating activities - discontinued operations		(3,164)
Net cash provided by operating activities	26,380	9,120
Investing activities		
Investment in property and equipment	(4,272)	(4,504
Investment in intangible assets	(699)	(262)
Principal payments received on lease receivable		104
Insurance recovery for property and equipment	871	_
Receipt of convertible debenture payment	-	738
Payment for land contracts	(478)	(769)
Cash portion of consideration paid in acquisitions, net of cash of acquired	(250)	(14,469
Net cash used in investing activities - continuing operations	(4,828)	(19,162
Net cash provided investing activities - discontinued operations		14,285
Net cash used in investing activities	(4,828)	(4,877
Financing activities		
Transfer of Employee Retention Credit	-	12,677
Proceeds from loan payable, net of transaction costs	3,137	23,872
Proceeds from options and warrants exercised	-	81
Loan principal paid	(18,048)	(40,359
Loan amendment fee paid and prepayment premium paid	-	(1,178)
Capital distributions paid to non-controlling interests	(1,564)	(3,415
Proceeds from private placement, net of share issuance costs	-	19,218
Payments made for financing obligations and finance lease	(316)	(941
Net cash (used in) provided by financing activities- continuing operations	(16,791)	9,955
Net cash used in financing activities- discontinued operations	-	(5,539)
Net cash (used in) provided by financing activities	(16,791)	4,416
Net increase in cash and cash equivalents and restricted cash during the period	4,761	8,659
Net effects of foreign exchange	383	(901
Cash and cash equivalents and restricted cash, beginning of the period	25,347	26,763
Cash and cash equivalents and restricted cash, beginning of the period	\$ 30,491 \$	34,521
	φ 50,π,21 φ	54,521
Supplemental disclosure with respect to cash flows		
Income taxes paid (refund received)	\$ (8,116) \$	(4,582)
Interest paid	\$ 12,599 \$	9,259
Lease termination fee paid	\$ 271 \$	_
Non-cash transactions		
Equity and warrant liability issued for acquisitions and non-controlling interest	\$ 4,674 \$	10,267
Shares issued for legal and liability settlement	s — s	794
Distribution payable to non-controlling interests	\$ 719 \$	—
Distribution payable to non-controlling interests	3 /15 3	

## TerrAscend Corp. Reconciliation of GAAP to Non-GAAP Financial Measures

(Amounts expressed in thousands of United States dollars, except for percentages)(unaudited)

The table below reconciles net loss from continuing operations to EBITDA from continuing operations and Adjusted EBITDA from continuing operations:

	For the Three Months Ended June 30, 2024 Jun	ded June 30, 2023	
Revenue, net	\$ 77,523	72,124	
Net loss	(6,237) \$	(13,476)	
Net loss margin %	-8.0 %	-18.7 %	
Loss from discontinued operations	—	621	
Loss from continuing operations	(6,237)	(12,855)	
Add (deduct) the impact of:			
Provision for income taxes	10,729	6,448	
Finance expenses	9,132	7,963	
Amortization and depreciation	4,993	4,991	
EBITDA from continuing operations	18,617	6,547	
Add (deduct) the impact of:			
Share-based compensation	1,960	1,981	
Loss from revaluation of contingent consideration	1,827	—	
Bad debt recovery	(4,169)	_	
Other one-time items	1,176	2,932	
Loss (gain) on lease termination and derecognition of ROU asset	(1,169)	_	
Gain on fair value of derivative liabilities and purchase option derivative assets	(2,922)	(215)	
Impairment of property and equipment	—	10	
Gain on disposal of fixed assets	(17)	—	
Unrealized and realized loss on investments	227	1,661	
Unrealized and realized foreign exchange loss (gain)	104	(101)	
Adjusted EBITDA from continuing operations	<u>\$ 15,634</u> <u>\$</u>	12,815	
Adjusted EBITDA Margin from continuing operations	20.2 %	17.8 %	

The table below reconciles Net cash provided by (used in) operating activities - continuing operations to Free Cash Flow:

	For the Three Months Ended			
	June 30, 2024 June 30, 2023			
Net cash provided by operating activities- continuing operations	\$ 13,129	\$	1,830	
Capital expenditures for property and equipment	(1,476)		(2,007)	
Free Cash Flow	\$ 11,653	\$	(177_)	

The table below reconciles Revenue, net to General & Administrative expenses excluding stock-based compensation as a percentage of revenue, net:

		For the Three Months Ended			
	June 30,	2024		June 30, 2023	
Revenue, net	\$	77,523	\$	72,124	
General & Administrative expenses		24,060		30,476	
Less: stock-based compensation		1,960		1,981	
General & Administrative expenses excluding stock-based compensation	\$	22,100	\$	28,495	
G&A excluding stock-based compensation as a % of revenue, net		28.5 %		39.5 %	